Scientific advances over the last four decades have steadily infused the Alzheimer's disease
(AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune …

For decades, the hypothesis that brain deposition of the amyloid β protein initiates
Alzheimer's disease has dominated research and clinical trials. Targeting amyloid β is …

Importance Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid
(Aβ) accumulation without symptoms. The duration of this phase differs greatly among …

Objective A clock relating amyloid positron emission tomography (PET) to time was used to
estimate the timing of biomarker changes in sporadic Alzheimer disease (AD). Methods …

Alzheimer's Disease (AD), the leading cause of senile dementia, is a progressive
neurodegenerative disorder affecting millions of people worldwide and exerting tremendous …

Clinical trials with anti-tau drugs will need to target individuals at risk of accumulating tau.
Our objective was to identify variables available in a research setting that predict future rates …

Background and Objectives To predict when cognitively normal individuals with brain
amyloidosis will develop symptoms of Alzheimer disease (AD). Methods Brain amyloid …

Alzheimer's disease biomarkers are becoming increasingly important for characterizing the
longitudinal course of disease, predicting the timing of clinical and cognitive symptoms, and …

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that affects memory,
thinking, behavior, and other cognitive functions. Although there is no cure, detecting AD …

Abstract Purpose In 2017, the Geneva Alzheimer's disease (AD) strategic biomarker
roadmap initiative proposed a framework of the systematic validation AD biomarkers to …